Rafael Conde-Camacho, Departamento de Hipertensión Pulmonar, Fundación Neumológica Colombiana, Bogotá; Doctorado en Biociencias, Universidad de La Sabana, Chía; Colombia
Mauricio Orozco-Levi, Departamento de Neumología, Fundación Cardiovascular de Colombia, Hospital Internacional de Colombia, Piedecuesta, Colombia
Eduardo Tuta-Quintero, Departamento de Hipertensión Pulmonar, Fundación Neumológica Colombiana, Bogotá; Facultad de Medicina, Universidad de La Sabana, Chía; Colombia
Ricardo Gómez-Palau, Departamento de Neumología, Clínica Imbanaco, Grupo Quirón Salud, Cali, Colombia
Alejandro Londoño, Departamento de Neumología, Clínica CardioVID, Medellín, Colombia
Luis F. Giraldo-Cadavid, Departamento de Hipertensión Pulmonar, Fundación Neumológica Colombiana, Bogotá; Facultad de Medicina, Universidad de La Sabana, Chía; Colombia
Pulmonary arterial hypertension (PAH) is a progressive and potentially life-threatening disease characterized by vascular remodeling and right ventricular dysfunction. While therapies targeting classical pathways exist, new options such as sotatercept and seralutinib show promise. However, their impact will depend on timely diagnosis and sustained treatment, which face challenges in Colombia due to structural inequities and the lack of specialized centers. The Colombian Pulmonary Hypertension Network (HAPredCO) has developed a model based on regional nodes and a central operational core that promotes research, equitable access to knowledge, and the ethical management of clinical data. Studies from the network have revealed low concordance between non-invasive diagnostic methods and hemodynamic measurements, as well as a high prevalence of malnutrition and a predominance of PAH associated with congenital heart disease. Moreover, altitude influences the clinical profile and therapeutic response, underscoring the need for risk assessment tools adapted to the local context.
Keywords: Pulmonary hypertension. Treatment. Pathophysiology. Right ventricle.
